二甲双胍促进儿童脑肿瘤放疗幸存者认知与神经恢复的试点临床试验评估
该研究在啮齿类动物颅脑放疗模型中观察到二甲双胍促进齿状回神经前体细胞恢复,并具有性别依赖的神经发生与认知效应;结果显示无临床相关安全问题和严重不良事件,所有认知结局均存在序列效应;在周期1完整数据亚组中,二甲双胍在陈述性记忆和工作记忆测试上优于安慰剂。
要点
- 儿童脑肿瘤颅脑放疗幸存者中,二甲双胍未出现临床相关安全问题或严重不良事件。
- 线性混合模型显示所有认知结局均存在序列效应,需在解释治疗效应时考虑。
- 周期1完整数据亚组中,二甲双胍在陈述性记忆和工作记忆测试上优于安慰剂。
核心结论
- 在儿童脑肿瘤长期幸存者中开展二甲双胍对认知与脑结构影响的临床试验是可行的,且二甲双胍在该人群中安全、可耐受。
- 该试点试验并非旨在检验二甲双胍对认知恢复和脑生长的疗效,但初步结果令人鼓舞,值得在大型多中心3期试验中进一步研究。
研究设计与样本
- 评估终点包括安全性、可行性、认知测试以及白质和海马的MRI测量;通过抽血监测安全性。
- 可行性通过招募率、药物依从性和程序依从性评估;采用线性混合模型分析认知和MRI结局与周期、序列和治疗的关系。
主要发现
- 在啮齿类动物颅脑放疗模型中,二甲双胍促进齿状回神经前体细胞恢复,并对神经发生和认知具有性别依赖效应。
- 人体试验中未发现与二甲双胍相关的临床相关安全问题,也无严重不良事件。
- 线性混合模型显示所有认知结局均存在序列效应。
- 在周期1具有完整数据的参与者亚组中,二甲双胍在陈述性记忆和工作记忆测试上的表现优于安慰剂。
关键数值与推荐
- 二甲双胍和安慰剂周期均为12周,交叉时洗脱期为10周。
- 可行性评估指标包括招募率、药物依从性和程序依从性。
临床怎么用
- 该试点试验提示在儿童脑肿瘤颅脑放疗幸存者中可开展二甲双胍认知恢复临床试验,且二甲双胍安全可耐受。
- 初步认知改善结果仅来自周期1完整数据亚组,尚不能作为临床推荐依据,需等待大型多中心3期试验验证。
局限性
- 该试点试验并非旨在检验二甲双胍对认知恢复和脑生长的疗效。
- 所有认知结局均存在序列效应,可能影响治疗效应解释。
- 认知改善结果仅基于周期1具有完整数据的参与者亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We asked whether pharmacological stimulation of endogenous neural precursor cells (NPCs) may promote cognitive recovery and brain repair, focusing on the drug metformin, in parallel rodent and human studies of radiation injury. In the rodent cranial radiation model, we found that metformin enhanced the recovery of NPCs in the dentate gyrus, with sex-dependent effects on neurogenesis and cognition. A pilot double-blind, placebo-controlled crossover trial was conducted (ClinicalTrials.gov, NCT02040376) in survivors of pediatric brain tumors who had been treated with cranial radiation. Safety, feasibility, cognitive tests and MRI measures of white matter and the hippocampus were evaluated as endpoints. Twenty-four participants consented and were randomly assigned to complete 12-week cycles of metformin (A) and placebo (B) in either an AB or BA sequence with a 10-week washout period at crossover. Blood draws were conducted to monitor safety. Feasibility was assessed as recruitment rate, medication adherence and procedural adherence. Linear mixed modeling was used to examine cognitive and MRI outcomes as a function of cycle, sequence and treatment. We found no clinically relevant safety concerns and no serious adverse events associated with metformin. Sequence effects were observed for all cognitive outcomes in our linear mixed models. For the subset of participants with complete data in cycle 1, metformin was associated with better performance than placebo on tests of declarative and working memory. We present evidence that a clinical trial examining the effects of metformin on cognition and brain structure is feasible in long-term survivors of pediatric brain tumors and that metformin is safe to use and tolerable in this population. This pilot trial was not intended to test the efficacy of metformin for cognitive recovery and brain growth, but the preliminary results are encouraging and warrant further investigation in a large multicenter phase 3 trial.
引用
- Ayoub R, Ruddy RM, Cox E, et al. Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nat Med. 2020. PMID: 32719487. doi:10.1038/s41591-020-0985-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。